Lexicon Pharmaceuticals Value Stock - Dividend - Research Selection

Lexicon pharmaceuticals

ISIN: US5288723027 , WKN: A14SSK

Market price date:
Market price:

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C

P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield	%
P/B
P/S

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!

How our site works ...

✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Description	Data
Symbol
Market Capitalization	USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet

Description of the company

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 clinical development for the treatment of diabetes; and LX9211 that is in Phase 1 clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,

NEWS

Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting

2026-04-17

Oral presentation highlights additional data from PROGRESS Phase 2b study of pilavapadin supporting selection of 10mg as optimal dose for Phase 3 development in DPNP New data on spasticity further...

Finnhub

How The Lexicon Pharmaceuticals (LXRX) Story Is Shifting Around Pilavapadin And Valuation Assumptions

2026-04-07

The fair value estimate for Lexicon Pharmaceuticals sits at US$3.36, with recent price target moves on the Street leaning on how analysts now frame pilavapadin and the broader risk profile of the pipeline. Higher targets are being linked to a 30% assumed probability of success for pilavapadin and expectations around a potential partnership, while more cautious voices point to execution and deal uncertainty that could challenge those assumptions. As you read on, you will see how to track these...

Yahoo

Avis Budget Group, Toyota Motor And Other Big Stocks Moving Lower In Monday's Pre-Market Session

2026-03-30

U.S. stock futures up, Dow gains 150 points. Avis Budget Group (CAR) shares fall 9.6% in pre-market. Other stocks lower in pre-market trading.

Benzinga

LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity Drug

2026-03-24

Lexicon Pharmaceuticals stock jumps as NVO launches phase I study of oral obesity candidate LX9851, advancing a promising partnered therapy.

Yahoo

Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo

2026-03-24

Additional analyses from the SCORED and SOTA-P-CARDIA studies provide further evidence of benefits across patient subgroups potentially related to sotagliflozin's mechanism of actionTHE WOODLANDS, Texas, March 24, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced three presentations of sotagliflozin clinical data during the American College of Cardiology (ACC) Annual Meeting. The congress is being held March 28-30 in New Orleans, Louisiana. Lexicon will presen

Yahoo

Novo Nordisk (CPSE:NOVO B) Valuation Check As LX9851 Expands Its Obesity Drug Pipeline

2026-03-23

Novo Nordisk (CPSE:NOVO B) has kicked off a Phase 1 trial of LX9851, an oral, non-incretin obesity drug licensed from Lexicon Pharmaceuticals, bringing fresh attention to the breadth of its weight loss pipeline. See our latest analysis for Novo Nordisk. Despite a steady stream of obesity drug developments and regulatory news, including the Wegovy HD approval and the LX9851 trial start, Novo Nordisk’s 30-day share price return of 21.11% and year to date share price return of 28.10% sit against...

Yahoo

Novo Nordisk Begins Study of Lexicon Oral Obesity Drug

2026-03-23

The study is investigating the safety and tolerability of LX9851, how it moves through the body and its physiological and biological impacts.

Yahoo

Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851

2026-03-23

LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders Lexicon has earned a second of three potential $10 million near-term milestone payments and is eligible to receive up to $1 billion in total upfront and milestone payments from the collaboration, plus royalties on net sales THE WOODLANDS, Texas, March 23, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) and Novo Nordisk A/S t

Yahoo

HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $6 Price Target

2026-03-23

HC Wainwright & Co. analyst Joseph Pantginis reiterates Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and maintains $6 price target.

Benzinga

Lexicon Pharmaceuticals And Novo Nordisk Initiate Phase 1 Study With LX9851, An Oral Non-incretin Development Candidate, For Obesity And Associated Metabolic Disorders

2026-03-23

In March 2025, Lexicon signed an exclusive license agreement with Novo Nordisk for LX9851 in obesity and associated metabolic disorders. Under the terms of the agreement, Novo Nordisk obtained an exclusive, worldwide

Benzinga

Lexicon Pharmaceuticals Value Stock - Dividend - Research Selection